Biotts is excited to announce our participation in the upcoming RESI Conference in Boston! This event is a prime opportunity to engage with early-stage investors and biotech innovators.

We are thrilled to share an important update on our latest innovation in diabetes treatment, featured in our Sunday Express article. Biotts has developed an innovative stick-on patch designed to regulate blood sugar levels more effectively and conveniently than traditional insulin injections.

We are pleased to share the latest in-vivo results from our ongoing research together with Bioton into our innovative transdermal insulin delivery system.

At SusHi Tech Tokyo 2024, our CEO Jan Hendriks provided an insightful presentation on our patented MTC-Y transdermal drug delivery technology and showcases our main 2 projects – Transdermal Insulin and Transdermal Semaglutide.

Biotts, in collaboration with Bioton S.A., has achieved a historic milestone by successfully delivering insulin through a transdermal patch, eliminating the need for injections.

At Biotts, our partnership with Bioton has been on an exciting journey towards revolutionizing transdermal insulin delivery. We are proud to share our key achievements so far and outline the path that lies ahead for this groundbreaking collaboration.